IL-3R alpha Antibody MAB301-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemIL-3R alpha Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberMAB301-100
Quantity100 ug (also 500 ug, 25 ug)
ApplicationsWestern Blot, Flow Cytometry, Immunohistochemistry, Neutralization, Immunocytochemistry, CyTOF-ready
Conjugate/TagUnconjugated
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
ReactivityHuman
TargetIL-3R alpha
IsotypeIgG1
Clone32703
HostMouse
ImmunogenS. frugiperda insect ovarian cell line Sf 21-derived recombinant human IL-3 R alpha/CD123, Lys20-Arg305, predicted, Accession # P26951
NCBI Full Gene Nameinterleukin 3 receptor subunit alpha
NCBI Gene AliasesCD123, IL3RAY, IL-3R-alpha, IL3RY, IL3RX, IL3R, hIL-3Ra
ClonalityMonoclonal
PurityProtein A or G purified from hybridoma culture supernatant
Brand/TrademarkR&D Systems, a Bio-Techne Brand
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Available conjugates: Unconjugated

Specificity: Detects human IL-3 R alpha/CD123 in direct ELISAs and Western blots

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic TargetCancersAugust 13, 2022Koni M, Castellano I, Venturelli E, Sarcinella A, Lopatina T, Grange C, Cedrino M, Femminò S, Cossu-Rocca P, Orrù S, et al.ab8245), anti-β-Actin (Abcam #ab8227), anti-CD31 (Abcam #ab28364), and anti-IL-3Rα/CD123 (R&D Systems #MAB301-100). Secondary antibodies conjugated with peroxidase were purchased from Cell Signalling Technologies (Danvers,

(2) Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogrammingOncogenesisOctober 10, 2020Lopatina T, Grange C, Cavallari C, Navarro-Tableros V, Lombardo G, Rosso A, Cedrino M, Pomatto MAC, Koni M, Veneziano F, et al.starved TEC was cultured for 24 h in the presence of 1 μg/ml Human IL-3Rα/CD123 MAb (R&D Systems, #MAB301-100, Clone 32703). Untreated TEC served as controls. For EV isolation, TEC, untreated or pretreated by blocking

(3) Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell levelNature medicineJanuary 1, 2019Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U.

(4) A dual role for the N-terminal domain of the IL-3 receptor in cell signallingNature communicationsJanuary 26, 2018Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, et al.

(5) Interleukin-3 enhances the migration of human mesenchymal stem cells by regulating expression of CXCR4Stem cell research & therapyJuly 14, 2017Barhanpurkar-Naik A, Mhaske ST, Pote ST, Singh K, Wani MR.

(6) Human Basophils Modulate Plasma Cell Differentiation and MaturationJournal of immunology (Baltimore, Md. : 1950)January 1, 2017Dijkstra D, Meyer-Bahlburg A.

(7) Graves' disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cellsPloS oneJanuary 1, 2015Leskela S, Serrano A, de la Fuente H, Rodríguez-Muñoz A, Ramos-Levi A, Sampedro-Nuñez M, Sánchez-Madrid F, González-Amaro R, Marazuela M.

IL-3R alpha Antibody